Hematologic Malignancy
Mature B-Cell Neoplasm
CI-CAN-00003258Explore in graph →
HematologicNon-malignant1,787 active trials44 approved drugs119 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00003258Explore in graph →
Clinical trials
6,664 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04624893 | A Multicenter, Retrospective Observational Study to Evaluate the Effectiveness and Safety of Polatuzumab Vedotin | unknown | — | 35 | Jiangsu Cancer Institute & HospitalOTHER | 1 | Nov 12, 2020 | clinicaltrials |
| NCT04624971 | A Novel Prognostic Model of NPI for Risk-Predicting and Clinical Decision-making in Diffuse Large B-Cell Lymphoma in the Rituximab Era | unknown | — | 2,000 | Sun Yat-sen UniversityOTHER | 1 | Nov 12, 2020 |
| clinicaltrials |
| NCT04622579 | Lenalidomide Combined With Rituximab as Front-line Therapy for DLBCL Patients Aged Over 80 Years(R2DLBCL80) | unknown | Phase 2 | 20 | Guangdong Provincial People's HospitalOTHER | 1 | Nov 10, 2020 | clinicaltrials |
| NCT04609150 | Vertebral Fat Quantitative MRI as a Marker of Bone Fragility in Multiple Myeloma (MYELOMEFRAGIQUANTI) | unknown | — | 100 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Nov 6, 2020 | clinicaltrials |
| NCT04612582 | Comparison of BTD and BCD Based Regimens in the Treatment of AL Amyloidosis | unknown | Phase 4 | 70 | Guangdong Provincial People's HospitalOTHER | 1 | Nov 3, 2020 | clinicaltrials |
| NCT01965977 | Bortezomib Maintenance in High Risk DLBCL(Borma) | unknown | Phase 2 | 59 | Samsung Medical CenterOTHER | 1 | Oct 23, 2020 | clinicaltrials |
| NCT03921879 | Safety and Efficacy of OT-82 in Participants With Relapsed or Refractory Lymphoma | unknown | Phase 1 | 50 | Oncotartis, Inc.INDUSTRY | 1 | Oct 23, 2020 | clinicaltrials |
| NCT04600947 | Study of LP002 for the Treatment of Patients With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma | unknown | Phase 2 | 69 | Taizhou HoudeAoke Biomedical Co., Ltd.INDUSTRY | 1 | Oct 23, 2020 | clinicaltrials |
| NCT04587388 | Towards Personalized Medicine for Refractory/Relapsed Follicular Lymphoma Patients: the Cantera/Lupiae Registry(LUPIAE) | unknown | — | 500 | European Hematology Association - Lymphoma GroupOTHER | 6 | Oct 14, 2020 | clinicaltrials |
| NCT03380039 | Clinical Study of CAR-BCMA T Cells in Patients With Refractory or Relapsed Multiple Myeloma | unknown | N/A | 6 | Xinhua Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Oct 12, 2020 | clinicaltrials |
| NCT03302403 | Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors | unknown | N/A | 18 | Kang YUOTHER | 1 | Oct 8, 2020 | clinicaltrials |
| NCT03716856 | Clinical Study of CAR-BCMA T in Patients With Refractory or Relapsed Multiple Myeloma | unknown | Phase 1 | 11 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Oct 8, 2020 | clinicaltrials |
| NCT03711864 | Safety and Efficacy of IM21 Car-t Cells in Patients With Recurrent or Refractory BCMA Positive Multiple Myeloma | unknown | Phase 1 | 15 | Peking Union Medical College HospitalOTHER | 1 | Sep 30, 2020 | clinicaltrials |
| NCT04447573 | Immunotherapy With BCMA CAR-T Cells in Treating Patients With Relapsed or Refractory Multiple Myeloma | unknown | N/A | 20 | Hebei Senlang Biotechnology Inc., Ltd.INDUSTRY | 1 | Sep 29, 2020 | clinicaltrials |
| NCT04398953 | A Study of TQ-B3525 Tablet in the Treatment of Relapsed / Refractory Mantle Cell Lymphoma (MCL) | unknown | Phase 2 | 102 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Sep 11, 2020 | clinicaltrials |
| NCT04544059 | Lenalidomide Plus R-CHOP for CNS Relapse Prophylaxis in Diffuse Large B-cell Lymphoma | unknown | Phase 2 | 87 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Sep 10, 2020 | clinicaltrials |
| NCT04537442 | Clinical Study to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in the Treatment of Elderly Patients With Relapsed or Refractory Multiple Myeloma | unknown | Phase 1 | 10 | Beijing Immunochina Medical Science & Technology Co., Ltd.INDUSTRY | 1 | Sep 3, 2020 | clinicaltrials |
| NCT04486872 | An Exploratory Clinical Trial of Autologous Humanized Anti-cluster of Differentiation Antigen 19/20(CD19/CD20) Dual Specific CAR-T Cells Injection | unknown | Phase 1 | 18 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Aug 26, 2020 | clinicaltrials |
| NCT04500431 | Clinical Study to Evaluate the Safety and Feasibility of spCART-269 Injection in the Treatment of MM | unknown | Phase 1 | 10 | Shanghai Tongji Hospital, Tongji University School of MedicineOTHER | 1 | Aug 5, 2020 | clinicaltrials |
| NCT04500561 | YY-20394 、GEMOX Treatment Diffuse Large B-cell Lymphoma Single Arm, Open, Multicentrized Phase 1b/2 Clinical Trial | unknown | Phase 1 / Phase 2 | 28 | Shanghai YingLi Pharmaceutical Co. Ltd.INDUSTRY | 0 | Aug 5, 2020 | clinicaltrials |
| NCT04496011 | Effect of the Cycloergometer in Patients Undergoing Hematopoietic Stem Cell Transplantation | unknown | N/A | 30 | Federal University of Health Science of Porto AlegreOTHER | 1 | Aug 3, 2020 | clinicaltrials |
| NCT03669445 | Study Association of Lenalidomide, Ixazomib, Dexamethasone and Daratumumab in Newly Diagnosed Standard Risk Multiple Myeloma(IFM2018-01) | unknown | Phase 2 | 45 | University Hospital, ToulouseOTHER | 1 | Jul 30, 2020 | clinicaltrials |
| NCT03679351 | "FU-IFM2009" Database Post IFM/DFCI 2009 Study(DB-FU-IFM2009) | unknown | — | 675 | University Hospital, ToulouseOTHER | 1 | Jul 30, 2020 | clinicaltrials |
| NCT04324879 | A Study of TQ-B3525 in the Treatment of Relapsed / Refractory Follicular Lymphoma (FL) | unknown | Phase 2 | 80 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Jul 1, 2020 | clinicaltrials |
| NCT04275583 | A Study to Evaluate the Tolerance and Pharmacokinetics of TQB3602 Capsule | unknown | Phase 1 | 40 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Jun 17, 2020 | clinicaltrials |
| NCT04425824 | Toripalimab Combine With Rituximab for Treatment of Relapsed Refractory CD20 Positive Diffuse Large B-cell Lymphoma | unknown | Phase 2 | 20 | Chinese Academy of Medical SciencesOTHER | 1 | Jun 16, 2020 | clinicaltrials |
| NCT04432402 | Lenalidomide in Combination With R-GemOx in First-line Treatment of Elderly Diffuse Large B Cell Lymphoma | unknown | N/A | 124 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jun 16, 2020 | clinicaltrials |
| NCT03042247 | Prospective Comparison Between FDG-PET/MR and FDG-PET/CT in Classical Hodgkin Lymphoma and DLBC Non-Hodgkin Lymphoma | unknown | — | 120 | Marco PicardiOTHER | 1 | Jun 12, 2020 | clinicaltrials |
| NCT04407845 | Atrial Fibrillation in Patients Receiving Ibrutinib(FABRIC) | unknown | — | 60 | European Georges Pompidou HospitalOTHER | 1 | Jun 9, 2020 | clinicaltrials |
| NCT04407858 | Cardiovascular Complications of Carfilzomib(ICARE) | unknown | — | 60 | European Georges Pompidou HospitalOTHER | 1 | Jun 9, 2020 | clinicaltrials |
| NCT04423549 | Predictive Value of a mRNA Signature and Liquid Biopsy in Diffuse Large B Cell Lymphoma | unknown | — | 800 | Sun Yat-sen UniversityOTHER | 1 | Jun 9, 2020 | clinicaltrials |
| NCT04412889 | A Study of BCMA/CD19 Dual-Target CAR-T Cell Immunotherapy for Relapsed or Refractory MM | unknown | Early Phase 1 | 18 | Hebei Yanda Ludaopei HospitalOTHER | 1 | Jun 2, 2020 | clinicaltrials |
| NCT04388735 | Multiple Myeloma (MM) Quality of Life (QOL) Study | unknown | — | 360 | Massachusetts General HospitalOTHER | 1 | May 14, 2020 | clinicaltrials |
| NCT04370405 | A Study of YY-20394 in Participants With Relapsed/Refractory Follicular Non-Hodgkin's Lymphoma | unknown | Phase 2 | 123 | Shanghai YingLi Pharmaceutical Co. Ltd.INDUSTRY | 1 | May 11, 2020 | clinicaltrials |
| NCT04379167 | A Phase 2 Clinical Study of YY-20394 in Patients With Relapsed/Refractory Follicular Lymphoma | unknown | Phase 2 | 140 | Shanghai YingLi Pharmaceutical Co. Ltd.INDUSTRY | 0 | May 7, 2020 | clinicaltrials |
| NCT04376957 | Pilot Study of an Oral Chemotherapy Teaching Tool to Improve Adherence in Patients With Multiple Myeloma | unknown | N/A | 60 | Hamilton Health Sciences CorporationOTHER | 0 | May 6, 2020 | clinicaltrials |
| NCT04364724 | CTFEA Myeloma Study | unknown | — | 200 | Tel-Aviv Sourasky Medical CenterOTHER_GOV | 0 | Apr 28, 2020 | clinicaltrials |
| NCT02733380 | Chidamide Combined With VDDT Regimen in the Relapse and Refractory Diffuse Large B Cell Lymphoma | unknown | Phase 2 | 20 | Henan Cancer HospitalOTHER_GOV | 1 | Apr 1, 2020 | clinicaltrials |
| NCT04127916 | Bendamustine Plus Rituximab for Mantle Cell Lymphoma: a Multicenter Retrospective Analysis(BR-MCL) | unknown | — | 40 | Samsung Medical CenterOTHER | 1 | Mar 18, 2020 | clinicaltrials |
| NCT02951728 | Decitabine Plus R-CHOP in Diffuse Large B-cell Lymphoma(DR-CHOP) | unknown | Phase 1 / Phase 2 | 58 | Ruijin HospitalOTHER | 1 | Mar 11, 2020 | clinicaltrials |
| NCT03600363 | A Clinical Trial of Metformin in the Maintenance of Non-Hodgkin's Lymphoma Patients | unknown | Phase 2 | 250 | Ruijin HospitalOTHER | 1 | Mar 11, 2020 | clinicaltrials |
| NCT04295018 | A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma | unknown | Phase 1 | 10 | Peking Union Medical College HospitalOTHER | 1 | Mar 4, 2020 | clinicaltrials |
| NCT03385096 | Mel vs BUCY+VP-16 Conditioning Regimen for MM Undergoing Auto-HSCT | unknown | Phase 2 / Phase 3 | 122 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Feb 25, 2020 | clinicaltrials |
| NCT03051841 | CKD-581 + Bortezomib + Dexamethasone in Patients With Previously Treated Multiple Myeloma | unknown | Phase 1 | 18 | Chong Kun Dang PharmaceuticalINDUSTRY | 1 | Feb 24, 2020 | clinicaltrials |
| NCT03150316 | CKD-581 + Lenalidomide + Dexamethasone in Patients With Previously Treated Multiple Myeloma | unknown | Phase 1 | 18 | Chong Kun Dang PharmaceuticalINDUSTRY | 1 | Feb 24, 2020 | clinicaltrials |
| NCT01619761 | NK Cells in Cord Blood Transplantation | unknown | Phase 1 | 13 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 11, 2020 | clinicaltrials |
| NCT03633045 | Observational Study of Ibrutinib Use in CLL | unknown | — | 70 | Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of HealthOTHER | 1 | Feb 10, 2020 | clinicaltrials |
| NCT04260490 | Multiple Myeloma and Environmental Exposure to Pesticides in the French West Indies: A Population Based Case-control Study.(MYELODOM) | unknown | — | 600 | Centre Hospitalier Universitaire de la GuadeloupeOTHER | 2 | Feb 7, 2020 | clinicaltrials |
| NCT02577783 | PDD vs PAD to Treat Initially Diagnosed MM | unknown | Phase 4 | 64 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Feb 5, 2020 | clinicaltrials |
| NCT04109872 | Lenalidomide Observational Study in Patients With Mantle Lymphoma in Relapse/Refraction. Spanish Programme RRMCL Results. | unknown | — | 25 | Fundación Pública Andaluza para la gestión de la Investigación en SevillaOTHER | 1 | Feb 5, 2020 | clinicaltrials |
Data updated 24 days agoSource updated Nov 12, 2020source: clinicaltrials